Search results for "Protease inhibitors"

showing 10 items of 98 documents

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease in…

2011

Abstract Background Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce. Methods Subjects with virological success on first-PI-regimens who switched to NNRTI therapy (NNRTI group) or to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The effect of the switch on the ongoing CD4+ trend was assessed by two-phase linear regression (TPLR), allowing us to evaluate whether a change in the CD4+ trend (hinge) occurred and the time of its occurrence. Furthermore, we described the evolution of the frequencies in CD4-count classes across four relevant time-points (baseline, before and immediately after…

AdultCD4-Positive T-LymphocytesMalemedicine.medical_treatmentProtease InhibitorHuman immunodeficiency virus (HIV)CD4+ T-cellHIV InfectionsBiologymedicine.disease_causeSettore MED/17 - MALATTIE INFETTIVENucleoside Reverse Transcriptase InhibitorTimelcsh:Infectious and parasitic diseasesZidovudineRetrospective Studieimmune system diseasesAntiretroviral Therapy Highly ActivemedicineHumansProtease inhibitor (pharmacology)HIV InfectionProtease Inhibitorslcsh:RC109-216Retrospective StudiesHIV; CD4+ T-cellProteaseCd4 t cellDrug SubstitutionBackground dataHIVvirus diseasesMiddle AgedVirologyHIV; AIDS; CD4; NRTIReverse Transcriptase InhibitorCD4 Lymphocyte CountInfectious DiseasesCD4-Positive T-LymphocyteReverse Transcriptase InhibitorsRitonavirFemaleAdult; Antiretroviral Therapy Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Time; Drug Substitution; Infectious Diseasesmedicine.drugHumanResearch Article
researchProduct

Inhibition of neuropeptide degradation suppresses sweating but increases the area of the axon reflex flare.

2013

The neuropeptides CGRP (calcitonin gene-elated peptide) and substance P (SP) mediate neurogenic inflammation. Both are degraded by the neutral endopeptidase (NEP) which can be blocked by phosphoramidon. The aim was to evaluate the effect of NEP inhibition on sweating and vasodilatation. Dermal microdialysis was performed on the skin of 39 subjects. Two fibres were perfused with phosphoramidon (0.01%, 0.02% or 0.2%), two with saline. Acetylcholine (ACh) was either added to the microdialysis perfusate (n = 30, 10(-2)  m) or thermoregulatory sweating was induced (n = 9). Co-application of phosphoramidon reduced cholinergic and thermoregulatory sweating. However, the flare size - a localized in…

AdultMaleMicrodialysismedicine.medical_specialtyCalcitonin Gene-Related PeptideNeuropeptideSubstance PSweatingDermatologyCalcitonin gene-related peptideSubstance PBiochemistrychemistry.chemical_compoundInternal medicineReflexmedicineHumansProtease InhibitorsMolecular BiologySkinNeurogenic inflammationintegumentary systemChemistryPhosphoramidonGlycopeptidesrespiratory systemAxonsEndocrinologyCholinergicFemaleNeprilysinAcetylcholinemedicine.drugBody Temperature RegulationExperimental dermatology
researchProduct

Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors

2005

BACKGROUND:The substitution of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) for protease inhibitors (PIs) has demonstrated its suitability to maintain virologic response. However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants.OBJECTIVE:To describe the virologic failures among 74 HIV-infected patients who switched from PIs to nevirapine.METHODS:Virologic failure was defined as any rebound of the plasma HIV-RNA (pVL) levels >1000 copies/mL on one occasion or 2 consecutive intermittent viremia episodes defined as increases of the pVL >20 copies/mL but <1000 copies/mL. Virolog…

AdultMaleNevirapineHIV InfectionsViremiaImmunopathologyDrug Resistance ViralHumansMedicinePharmacology (medical)Protease inhibitor (pharmacology)NevirapineProspective StudiesSidabiologyReverse-transcriptase inhibitorbusiness.industryHIV Protease InhibitorsMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseVirologyToxicityHIV-1FemaleViral diseasebusinessFollow-Up Studiesmedicine.drugAnnals of Pharmacotherapy
researchProduct

Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: A case report

2002

Reversible posterior leukoencephalopathy syndrome (RPLS) is an uncommon entity related to multiple and different pathologies, the most common being hypertensive crisis. It is believed to be secondary to the breakdown on the blood-brain barrier. At the beginning, it is undistinguishable from other leukoencephalopathies. However, the disappearance of brain lesions after removal of the potential cause, establish the differential diagnosis with other leukoencephalopathies. We present the case of an HIV-infected patient with a RPLS related to a hypertensive crisis short after the initiation of indinavir-containing highly active antiretroviral therapy. Once blood pressure was controlled and indin…

AdultMalePathologymedicine.medical_specialtyHypertensive encephalopathymedicine.medical_treatmentHIV InfectionsIndinavirIndinavirAntiretroviral Therapy Highly ActiveHypertensive EncephalopathyInternal MedicinemedicineHumansChemotherapymedicine.diagnostic_testbusiness.industryProgressive multifocal leukoencephalopathyvirus diseasesMagnetic resonance imagingHIV Protease Inhibitorsmedicine.diseaseMagnetic Resonance ImagingHyperintensityNelfinavirDifferential diagnosisbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors

2015

Abstract Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We assessed the foremost ethical issues in hepatitis C virus therapy with 1st generation protease inhibitors using the personalist ethical framework within the health technology assessment methodology. Our aim was to identify values at stake/in conflict and to support both the physicians’ choices in hepatitis C therapy and social (macro-) allocation decision-making. The ethical assessment indicates that: (1) safety/effectiveness profile of treatment is guaranteed if its use is restricted to the patients subgroups who may benefit from it; (2) patients shoul…

AdultMalehepatitis C virusmedicine.medical_specialtyPathologyCost-Benefit AnalysisHepatitis C virusDecision MakingProtease InhibitoreducationAlternative medicineHepacivirusDirect-acting antiviralmedicine.disease_causeAntiviral AgentsSettore MED/02 - Storia Della MedicinaResource (project management)medicineHumansProtease InhibitorsEthics MedicalEthichealth technology assessmentCost-Benefit AnalysiDeferralIntensive care medicineEthical frameworkdirect-acting antiviralsAgedAntiviral AgentSettore MED/12 - GastroenterologiaHepaciviruHepatologybusiness.industryGastroenterologyHealth technologyHepatitis CMiddle AgedSettore MED/43 - MEDICINA LEGALEmedicine.diseaseHepatitis CethicsFirst generationDrug Therapy CombinationFemaleHepatitis C virubusinessHuman
researchProduct

Transmission of Drug-Resistant HIV Type 1 Strains in HAART-Naive Patients: A 5-Year Retrospective Study in Sicily, Italy

2010

The transmission of drug-resistant HIV-1 strains might compromise the efficacy of current first-line antiretroviral (ARV) regimens. Between 2004 and 2008, HIV-1 reverse transcriptase (RT) and protease (PR) genes of 108 ARVnaive Sicilian patients were amplified and sequenced to describe the prevalence of ARV resistance mutations among HAART-naive HIV-1-infected individuals. The frequency of transmitted drug resistance mutations (DRAMs) was determined by using genotypic interpretation algorithms. The proportion of HAART-naive HIV- 1-infected patients in Sicily increased from 18.4% to 23.5% during 2004–2008. Among naive patients, the overall prevalence of DRAMs was 15.7% [17/108; 95% CI: 9.4–2…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMolecular Sequence DataImmunologyHIV InfectionsDrug resistanceSettore MED/42 - Igiene Generale E ApplicataVirusYoung AdultAntiretroviral Therapy Highly ActiveVirologyMolecular geneticsDrug Resistance ViralGenotypePrevalencemedicineHumansChildSicilyAgedRetrospective StudiesHAART-naive HIV-1 drug resistanceProteaseMolecular epidemiologybiologyInfantvirus diseasesHIV Protease InhibitorsMiddle Agedbiology.organism_classificationVirologyReverse transcriptaseInfectious DiseasesChild PreschoolMutationLentivirusHIV-1Reverse Transcriptase InhibitorsFemaleAIDS Research and Human Retroviruses
researchProduct

A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis

2001

BACKGROUND The aim was to evaluate the clinical performance of alpha1-antichymotrypsin prostate-specific antigen (PSA-ACT) for early diagnosis of prostate cancer (PCa) in a multicenter trial. METHODS Three hundred sixty-seven white men with PCa and 290 with benign prostatic hyperplasia (BPH) with tPSA concentrations between 2 and 20 μg/L were analyzed. The Elecsys system 2010 (Roche Diagnostics, Germany) was used for determination of total PSA (tPSA) and free PSA (fPSA). The PSA-ACT test was a prototype assay used on the ES system (Roche Diagnostics). RESULTS The median concentrations of tPSA (PCa: 8.43 μg/L vs. BPH: 6.60 μg/L) and PSA-ACT (8.30 μg/L vs. 6.46 μg/L) were significantly differ…

AdultMalemedicine.medical_specialtyalpha 1-AntichymotrypsinUrologyProstatic HyperplasiaUrologyEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesStatistics NonparametricProstate cancerProstateMulticenter trialmedicineHumansProtease InhibitorsAlpha1 AntichymotrypsinAgedAged 80 and overGynecologyReceiver operating characteristicbusiness.industryArea under the curveAntibodies MonoclonalProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseClinical trialProstate-specific antigenmedicine.anatomical_structureROC CurveOncologybusinessThe Prostate
researchProduct

Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis

1998

Asthma and chronic bronchitis are inflammatory diseases with extracellular matrix (ECM) remodeling and collagen deposition. Collagen homeostasis is controlled by metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). We evaluated MMP and TIMP balance in induced sputum of 10 control, 31 untreated asthmatic, and 16 chronic bronchitic subjects. We first performed zymographic analysis to identify the profile of MMPs. Zymography revealed a similar MMPs profile in all populations studied and that MMP-9 was the major enzyme released. We then measured, using enzyme immunoassay, the concentrations of MMP-9 and of its inhibitor TIMP-1 and evaluated whether airflow limitation m…

AdultPulmonary and Respiratory MedicineChronic bronchitisAdolescentNeutrophilsCell CountEnzyme-Linked Immunosorbent AssayMatrix metalloproteinaseCritical Care and Intensive Care MedicinePathogenesisLeukocyte CountSurface-Active AgentsForced Expiratory VolumemedicineHomeostasisHumansProtease InhibitorsCollagenasesBronchitisAgedAsthmaTissue Inhibitor of Metalloproteinase-1business.industryMacrophagesRespiratory diseaseSputumSodium Dodecyl SulfateMiddle AgedTissue inhibitor of metalloproteinasemedicine.diseaseAsthmaExtracellular Matrixrespiratory tract diseasesAirway ObstructionMatrix Metalloproteinase 9Chronic DiseaseImmunologyBronchitisSputumElectrophoresis Polyacrylamide GelCollagenmedicine.symptomPulmonary Ventilationbusiness
researchProduct

Effects of Parietaria judaica pollen extract on human microvascular endothelial cells

2008

Abstract Pollinosis from Parietaria judaica is one of the main causes of allergy in the Mediterranean area. The present study is designed to assess if P. judaica pollens contain bioactive compounds able to elicit a functional response in endothelial cells. We have demonstrated that addition of pollen extract to human lung microvascular endothelial cells (HMVEC-L) induces a modification of cell morphology, actin cytoskeletal rearrangements and an increase in endothelial cell permeability. We further showed that the treatment of endothelial cells with pollen extract causes an increase of E-selectin and VCAM-1 protein levels as well as an increase of IL-8 production. The stimulation of cell–ce…

AllergyNeutrophilsBiophysicsVascular Cell Adhesion Molecule-1parietaria judaicaBiologymedicine.disease_causeCell morphologyBiochemistryPermeabilitycell adhesion moleculesPollenCell AdhesionmedicineHumansProtease InhibitorsCytoskeletonLungMolecular BiologyCells CulturedActinPlant ExtractsCell adhesion moleculeInterleukin-8Cell BiologyAdhesionbiology.organism_classificationCapillariesCell biologyEndothelial stem cellParietariaImmunologyParietaria judaicaendothelial cellPollenEndothelium VascularE-Selectin
researchProduct

Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.

2004

The design and successful clinical implementation of cancer vaccines targeting the induction of T-cell mediated immunity is a rapidly evolving field that is hampered by an empirical selection of antigen and adjuvant. In particular, vaccines using defined tumor-associated peptide epitopes elicit only a restricted T-cell repertoire in a minority of patients. In this regard, vaccines comprising the whole spectrum of antigens presented by individual autologous tumors would be advantageous. In an in vitro model, we evaluated the capacity of naturally processed Epstein-Barr virus-transformed B-lymphoblastoid-cell line (LCL)-derived peptides to activate virus-specific CD8+ T cells of seropositive …

AntigenicityHerpesvirus 4 HumanT cellImmunologyHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesIn Vitro TechniquesLymphocyte ActivationCancer VaccinesEpitopeMonocytesEpitopesAntigenHLA AntigensmedicineImmunology and AllergyHumansProtease InhibitorsAntigen PresentationImmunogenicityHistocompatibility Antigens Class IDendritic cellDendritic CellsCell Transformation ViralMolecular biologyCell biologyClone Cellsmedicine.anatomical_structureProteasome inhibitorLymphocyte Culture Test MixedProteasome Inhibitorsmedicine.drugJournal of immunological methods
researchProduct